Literature DB >> 1452932

Pressure overload-induced cardiac hypertrophy with and without dilation.

A K Randhawa1, P K Singal.   

Abstract

OBJECTIVES: The present study was designed to produce a small animal model showing compensated hypertrophy followed by congestive heart failure within a reasonable time period.
BACKGROUND: Although there are various large animal experimental models of hypertrophy and heart failure, the occurrence of these two stages within a reasonable time period has not been shown very successfully in small animals.
METHODS: A mildly constricting band was placed around the ascending aorta of very young guinea pigs (mean age 25 +/- 3 days) to impose a gradually increasing pressure overload. The animals were examined at different postoperative intervals up to 20 weeks.
RESULTS: At 10 weeks, there was a 56% increase in ventricular weight/body weight ratio, a 33% increase in left ventricular wall thickness and a significant increase in left ventricular systolic pressure. The animals with 20 weeks of banding had developed various clinical symptoms of congestive heart failure including dyspnea, cyanotic appearance of the extremities, hydrothorax and ascites. Although at this stage there was 86% hypertrophy, the increase in wall thickness was only 20%, indicating cardiac dilation. Depressed left ventricular systolic pressure and increased left ventricular end-diastolic pressure and the increase in wet weight/dry weight ratio in the lungs and liver at 20 weeks also indicated the occurrence of heart failure. The collagen content in the heart of animals with banding for 10 and 20 weeks was 160% and 240%, respectively, of that in corresponding sham control animals.
CONCLUSIONS: The data suggest that the heart was in a stage of compensated hypertrophy for up to 10 weeks, whereas heart failure was seen at 20 weeks. The two functional stages, compensatory hypertrophy followed by prolonged failure, make this model appropriate for studies on the transition of heart hypertrophy to congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1452932     DOI: 10.1016/0735-1097(92)90452-s

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  7 in total

1.  Lethal Arg9Cys phospholamban mutation hinders Ca2+-ATPase regulation and phosphorylation by protein kinase A.

Authors:  Kim N Ha; Larry R Masterson; Zhanjia Hou; Raffaello Verardi; Naomi Walsh; Gianluigi Veglia; Seth L Robia
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

2.  Myocardial oxidative stress changes during compensated right heart failure in rats.

Authors:  J Pichardo; V Palace; F Farahmand; P K Singal
Journal:  Mol Cell Biochem       Date:  1999-06       Impact factor: 3.396

3.  Inhibition of tissue repair by spironolactone: role of mineralocorticoids in fibrous tissue formation.

Authors:  S H Slight; V K Chilakamarri; S Nasr; A K Dhalla; F J Ramires; Y Sun; V K Ganjam; K T Weber
Journal:  Mol Cell Biochem       Date:  1998-12       Impact factor: 3.396

4.  B-type natriuretic peptide and wall stress in dilated human heart.

Authors:  P Alter; H Rupp; M B Rominger; A Vollrath; F Czerny; J H Figiel; P Adams; F Stoll; K J Klose; B Maisch
Journal:  Mol Cell Biochem       Date:  2008-05-07       Impact factor: 3.396

Review 5.  Oxidative stress and heart failure.

Authors:  N Singh; A K Dhalla; C Seneviratne; P K Singal
Journal:  Mol Cell Biochem       Date:  1995 Jun 7-21       Impact factor: 3.396

6.  Olive oil protects against progression of heart failure by inhibiting remodeling of heart subsequent to myocardial infarction in rats.

Authors:  Abd Al-Rahman Al-Shudiefat; Ana Ludke; Akshi Malik; Davinder S Jassal; Ashim K Bagchi; Pawan K Singal
Journal:  Physiol Rep       Date:  2022-08

Review 7.  Heart Plasticity in Response to Pressure- and Volume-Overload: A Review of Findings in Compensated and Decompensated Phenotypes.

Authors:  Fotios G Pitoulis; Cesare M Terracciano
Journal:  Front Physiol       Date:  2020-02-13       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.